With #GDFatherNeo #ESMO26 We brought visugromab+nivo combination neoadjuvantly in pts with MIBC after the initial phase 1 data in refractory setting.
33% CR rates vs 8% Nivo+placebo
All pCR pts still event-free (median FUP 15.7m)
Only 1 relapse event in major responders in N+V arm (pTa relapse)
4/5 pCR skipped RC in N+V arm.
Safety was quite good.
Pre-existing CD8+ infiltration associated with N+V Response.
It was an illuminating academic-industry collaboration for me.
Results simultaneously released today in @NatureMedicine
@myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @giannatempopatr @DrIacovelli @ciccarese_c and Many more @SanRaffaeleMI @MyUniSR

https://www.nature.com/articles/s41591-026-04740-9